Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multi-center Study to Evaluate the Efficacy and Safety of GB001 as Maintenance Therapy in Adult Subjects With Moderate to Severe Asthma

Trial Profile

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multi-center Study to Evaluate the Efficacy and Safety of GB001 as Maintenance Therapy in Adult Subjects With Moderate to Severe Asthma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GB 001 (Primary)
  • Indications Allergic asthma; Asthma
  • Focus Therapeutic Use
  • Acronyms LEDA
  • Sponsors Gossamer Bio
  • Most Recent Events

    • 12 Nov 2019 According to a Gossamer Bio media release, results of post hoc analysis from the study were presented at the European Respiratory Society (ERS) International Congress 2019.
    • 08 Aug 2019 According to a Gossamer Bio media release, full results from the study are expected in the second half of 2020.
    • 14 May 2019 According to a Gossamer Bio media release, results from an interim analysis expected in the first half of 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top